The estimated Net Worth of Edward T Anderson is at least $681 Tisíc dollars as of 31 May 2023. Edward Anderson owns over 1,805,416 units of Lyra Therapeutics stock worth over $680,871 and over the last 5 years Edward sold LYRA stock worth over $0.
Sign up
Edward Anderson LYRA stock SEC Form 4 insiders trading
Edward has made over 3 trades of the Lyra Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Edward bought 1,805,416 units of LYRA stock worth $4,387,161 on 31 May 2023.
The largest trade Edward's ever made was buying 2,488,150 units of Lyra Therapeutics stock on 12 April 2022 worth over $10,499,993. On average, Edward trades about 649,081 units every 160 days since 2020. As of 31 May 2023 Edward still owns at least 2,521,745 units of Lyra Therapeutics stock.
You can see the complete history of Edward Anderson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Lyra Therapeutics
Over the last 5 years, insiders at Lyra Therapeutics have traded over $0 worth of Lyra Therapeutics stock and bought 19,620,470 units worth $85,899,322 . The most active insiders traders include Advisors Llcperceptive Life..., Edward T Anderson a Gp, Llcdamore Richard Anort.... On average, Lyra Therapeutics executives and independent directors trade stock every 76 days with the average trade being worth of $311,619. The most recent stock trade was executed by Harlan Waksal on 10 November 2023, trading 25,000 units of LYRA stock currently worth $74,000.
What does Lyra Therapeutics do?
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
What does Lyra Therapeutics's logo look like?
Complete history of Edward Anderson stock trades at Lyra Therapeutics
Lyra Therapeutics executives and stock owners
Lyra Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Maria Palasis Ph.D.,
CEO, Pres & Director -
R. Donald Elsey MBA,
Advisor -
Dr. Robert Richard Ph.D.,
Sr. VP of R&D -
Pamela E. Nelson,
Sr. VP of Regulatory Affairs -
Vineeta Belanger Ph.D.,
Sr. VP of Clinical Affairs -
Corinne Noyes,
Sr. VP of Commercial Strategy & Market Devel. -
Ray Knox,
VP of Operations -
Jason Cavalier,
Chief Financial Officer -
Dr. Carmichael S. Roberts Jr., Ph.D.,
Co-Founder -
Dr. Harlan W. Waksal M.D.,
Exec. Chairman -
Maria Palasis,
President & CEO -
Carmichael Roberts,
10% owner -
Robert Langer,
Director -
Advisors Llcperceptive Life...,
-
George M Whitesides,
Director -
Venture Management Co. V, L...,
-
R Don Elsey,
CFO, Treasurer & Secretary -
Gp, Llcdamore Richard Anort...,
-
Private Equity Gp I, Llc So...,
-
Laura Edgerly Pflug,
See Remarks -
Corinne Noyes,
See Remarks -
Michael Seth Altman,
-
Venture Management Co Iv Ll...,
-
Advisors Llcedelman Joseph ...,
-
Jason Cavalier,
Chief Financial Officer -
Robert E. Richard,
SVP, Technical Operations -
Pamela E. Nelson,
SVP, Regulatory Affairs -
Harlan Waksal,
Executive Chair -
Richard Nieman,
Chief Medical Officer -
John E Bishop,
Chief Technology Officer -
C Ann Merrifield,
-
James R Tobin,
-
Nancy Lynn Md Snyderman,
-
Konstantin Poukalov,
-
Edward T Anderson,
-
W Bradford Smith,